Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Grazoprevir + Peg-IFN + RBV in Treatment-Naïve Genotype 1 Hepatitis C
NCT01353911Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2011
- Primary completion
- Jan 2013
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of grazoprevir in hepatitis C (HCV) (8 arms), sponsored by Merck & Co. Primary endpoints: Complete Early Viral Response at 12 weeks, Adverse Events and 1 more. Started Jun 2011; status: completed.
02
Drugs
grazoprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01353911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01353911.